Ontvang nu dagelijks onze kooptips!

word abonnee
IEX 25 jaar
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
Markt vandaag Koersen Forum Premium IEX Expert
Home  /   Forum   /   BioPharma   /   Insmed, in de gaten houden

BioPharma« Terug naar discussie overzicht

Insmed, in de gaten houden

Volgen
20.047 Posts
Pagina: «« 1 ... 845 846 847 848 849 ... 1003 »» | Laatste | Omlaag ↓
  1. [verwijderd] 13 juni 2006 14:13
    Press Release Source: Insmed Incorporated

    Court Dismisses Baseless Unfair Business Practices Lawsuit That Was Brought Against Insmed
    Tuesday June 13, 8:04 am ET

    RICHMOND, Va.--(BUSINESS WIRE)--June 13, 2006--Insmed Incorporated (Nasdaq:INSM - News): On June 9, 2006, the United States District Court for the Northern District of California (Judge Saundra Brown Armstrong) granted Insmed's Motion to Dismiss the Complaint filed by Tercica, Inc. in the case Tercica, Inc. vs. Insmed Incorporated. The Complaint, filed and amended in December 2005, alleged violations of the California Business and Professions Code and the federal Lanham Act for allegedly false and misleading statements made by Insmed. In dismissing the Complaint, the Court ruled, among other things, that Tercica had not met its burden of establishing that the alleged statements made by Insmed constitute "false advertising", or that the Court had jurisdiction over Insmed in this case and that the venue was proper. Further, by dismissing Tercica's complaint without leave to amend, the Court recognized that the deficiencies in Tercica's lawsuit cannot be cured by filing another lawsuit against Insmed in the United States District Court for the Northern District of California. Insmed previously notified Tercica that Insmed would seek fees and costs related to Tercica's baseless lawsuit. Given the Court's ruling, Insmed will pursue this option.


    "We are pleased that the Court ruled that Tercica's complaint was without merit and upheld Insmed's right to inform the investment community about our product development activities related to IPLEX(TM) without violating the Lanham Act," stated Geoffrey Allan, Insmed's Chief Executive Officer. "In line with Tercica's continuing preference to litigate, Tercica has indicated they have filed a new lawsuit against Insmed in the Virginia courts that is similar to the lawsuit dismissed in California. As with the California case, Insmed will vigorously defend its position and right to inform the investment community about product development activities."
  2. [verwijderd] 13 juni 2006 14:13
    Press Release Source: Insmed Incorporated

    Court Dismisses Baseless Unfair Business Practices Lawsuit That Was Brought Against Insmed
    Tuesday June 13, 8:04 am ET

    RICHMOND, Va.--(BUSINESS WIRE)--June 13, 2006--Insmed Incorporated (Nasdaq:INSM - News): On June 9, 2006, the United States District Court for the Northern District of California (Judge Saundra Brown Armstrong) granted Insmed's Motion to Dismiss the Complaint filed by Tercica, Inc. in the case Tercica, Inc. vs. Insmed Incorporated. The Complaint, filed and amended in December 2005, alleged violations of the California Business and Professions Code and the federal Lanham Act for allegedly false and misleading statements made by Insmed. In dismissing the Complaint, the Court ruled, among other things, that Tercica had not met its burden of establishing that the alleged statements made by Insmed constitute "false advertising", or that the Court had jurisdiction over Insmed in this case and that the venue was proper. Further, by dismissing Tercica's complaint without leave to amend, the Court recognized that the deficiencies in Tercica's lawsuit cannot be cured by filing another lawsuit against Insmed in the United States District Court for the Northern District of California. Insmed previously notified Tercica that Insmed would seek fees and costs related to Tercica's baseless lawsuit. Given the Court's ruling, Insmed will pursue this option.
    ADVERTISEMENT




    "We are pleased that the Court ruled that Tercica's complaint was without merit and upheld Insmed's right to inform the investment community about our product development activities related to IPLEX(TM) without violating the Lanham Act," stated Geoffrey Allan, Insmed's Chief Executive Officer. "In line with Tercica's continuing preference to litigate, Tercica has indicated they have filed a new lawsuit against Insmed in the Virginia courts that is similar to the lawsuit dismissed in California. As with the California case, Insmed will vigorously defend its position and right to inform the investment community about product development activities."

    About Insmed

    Insmed is a biopharmaceutical company focused on the development and commercialization of drugs for the treatment of metabolic diseases and endocrine disorders with unmet medical needs. For more information, please visit www.insmed.com.

    Forward Looking Statements

    Statements included within this press release, which are not historical in nature, may constitute forward-looking statements for the purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding the pending litigation and or future ability to conduct our business as now conducted and as it is currently proposed to be conducted. Such forward-looking statements are subject to numerous risks and uncertainties, including but not limited to the uncertainty of the outcome of any litigation with Tercica. We can give no assurances that we would be successful in any litigation or that such litigation would not have a material adverse effect on our business, financial condition and results of operation. Furthermore, we may not be able to afford the expense of defending against such a claim. As a result of these and other risks and uncertainties, actual results may differ materially from those described in this press release. For further information with respect to factors that could cause actual results to differ from expectations, reference is made to reports filed by the Company with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended.
  5. [verwijderd] 13 juni 2006 14:18
    quote:

    rac69 schreef:

    [quote=Rieltijm]
    Bijna gelijkertijd rac, beter 2x dan niet.....

    Ries
    [/quote]

    zekers.koers reageert ook meteen.

    Pre-Market (RT-ECN): 1.55 0.14 (9.93%)
    Yep, ziet er inderdaad een stuk gezelliger uit... maar ik kijk wel weer vanavond om 22.00 uur locale tijd (lees: hier), want met Insmed (en het verrotte beursklimaat) weet je het nooit.....
    Sterkte
    Ries
  13. [verwijderd] 13 juni 2006 14:35
    Een op meerdere fronten mooie dag vandaag!!
    Het zou zo maar eens kunnen, dat de IB-ers vandaag het tapijt onder TRCA uittrekken en instappen in Insmed.
    Het feit, dat ze dan hun geld kwijt zijn, heet in bedrijfstermen: sunk cost.
    En ja, you win some, you lose some!

    Dus nu: Lazard achterna met hun $4.

    Psycho
    gaat diep in de wijnkelder een bijzonder flesje uitzoeken om het te vieren
  17. Striker_ 13 juni 2006 14:41
    hoezo de beste advocaten?
    Denken jullie dat TRCA voorliegt in de SEC filings dan???

    Tercica, Inc. today filed a complaint in the U.S. District Court for the Eastern District of Virginia, Richmond division alleging Insmed Incorporated violated the Lanham Act and related statutes relating to false advertising and unfair competition. This action was taken after the presiding Judge for the U.S. District Court for the Northern District of California, the Honorable Saundra Brown Armstrong, dismissed on June 9, 2006 Tercica's complaint for the same violations on the basis that she could not exercise jurisdiction over Insmed, which is based in Virginia. Her ruling also indicated that the complaint should establish that the requisite false statements were disseminated to consumers of Increlex™, e.g., the physicians who purchase and prescribe Increlex, rather than solely to investors. Tercica's re-filing adds new allegations of false and misleading advertising that Insmed disseminated specifically to pediatric endocrinologists, who for purposes of the Lanham Act and related statutes are among the relevant community of consumers affected.

    Of denken jullie soms ook dat ze het niet nog een keer indienen?
    Wat heeft TRCA te verliezen?? juist, NIETS. Alleen nog wat meer geld van hun investeerders.
20.047 Posts
Pagina: «« 1 ... 845 846 847 848 849 ... 1003 »» | Laatste |Omhoog ↑

Direct naar Forum

Markt Vandaag

Stijgers

instrument koers absoluut verschil relatief verschil
AZERION 1,208 +0,06 +5,04%
EBUSCO HOLDING 0,909 +0,04 +4,72%
Brunel 8,700 +0,35 +4,19%
PostNL 1,046 +0,04 +3,56%
THEON INTERNAT 10,520 +0,30 +2,94%
Pharming 0,724 +0,02 +2,70%
HEIJMANS KON 28,150 +0,65 +2,36%
Galapagos 26,420 +0,58 +2,24%
CTP 15,140 +0,26 +1,75%
FASTNED 21,500 +0,35 +1,65%
ALLFUNDS GROUP 5,405 +0,09 +1,60%
OCI 11,210 +0,17 +1,49%
Alfen N.V. 11,700 +0,15 +1,30%
Eurocommercial Properties 23,500 +0,30 +1,29%
Sif Holding 12,100 +0,14 +1,17%
Aperam 26,980 +0,28 +1,05%
Ahold Delhaize 32,870 +0,34 +1,05%
ACOMO 17,460 +0,18 +1,04%
UNILEVER PLC 56,760 +0,58 +1,03%
Wereldhave 13,980 +0,12 +0,87%
ASCX 1.176,02 +9,97 +0,86%
NSI 19,660 +0,16 +0,82%
KPN 3,669 +0,03 +0,77%
Nedap N.V. 53,000 +0,40 +0,76%
UMG 22,660 +0,16 +0,71%
ArcelorMittal 23,150 +0,16 +0,70%
JDE PEET'S 18,890 +0,13 +0,69%
RANDSTAD NV 41,260 +0,26 +0,63%
INPOST 17,560 +0,10 +0,57%
Flow Traders 21,140 +0,12 +0,57%
Sligro 10,860 +0,06 +0,56%
Fagron 18,660 +0,10 +0,54%
Heineken 70,080 +0,36 +0,52%
Van Lanschot Kempen NV 42,200 +0,20 +0,48%
Akzo Nobel 55,260 +0,24 +0,44%
WDP 20,640 +0,08 +0,39%
NX FILTRATION 4,080 +0,01 +0,37%
AALBERTS NV 34,020 +0,12 +0,35%
RELX 44,700 +0,14 +0,31%
IMCD 139,850 +0,40 +0,29%
TKH 30,940 +0,08 +0,26%
SBM Offshore 17,170 +0,04 +0,23%
ING 14,470 +0,03 +0,22%
Aegon 5,902 +0,01 +0,20%
Wolters Kluwer 157,650 +0,30 +0,19%
ADYEN NV 1.387,400 +2,20 +0,16%
Philips Koninklijke 25,800 +0,04 +0,16%
PROSUS 38,065 +0,05 +0,14%
AMX 862,54 +0,85 +0,10%
Corbion 21,720 0,00 0,00%
Vastned 24,400 0,00 0,00%

Dalers

instrument koers absoluut verschil relatief verschil
AMG Critical Materials N.V. 14,280 -0,51 -3,45%
Air France-KLM 7,238 -0,25 -3,31%
JUST EAT TAKEAWAY 14,485 -0,37 -2,46%
BESI 108,450 -2,45 -2,21%
CM.COM 5,840 -0,13 -2,18%
ASMI 493,400 -9,80 -1,95%
ASML 627,700 -12,30 -1,92%
Accsys 0,577 -0,01 -1,54%
RENEWI 6,700 -0,09 -1,33%
B&S Group SA 4,315 -0,05 -1,26%
TomTom 5,195 -0,05 -1,05%
SIGNIFY NV 20,780 -0,22 -1,05%
Fugro 16,670 -0,13 -0,77%
ForFarmers 3,215 -0,03 -0,77%
DSM FIRMENICH AG 104,100 -0,80 -0,76%
Basic-Fit 21,160 -0,16 -0,75%
Kendrion 10,660 -0,08 -0,74%
ASR Nederland 44,390 -0,25 -0,56%
NN Group 43,660 -0,24 -0,55%
Avantium 2,125 -0,01 -0,47%
Arcadis 62,050 -0,25 -0,40%
SHELL PLC 30,760 -0,11 -0,37%
Vopak 44,000 -0,16 -0,36%
ABN AMRO BANK N.V. 14,560 -0,04 -0,24%
BAM 3,914 -0,01 -0,15%
EXOR NV 93,800 -0,10 -0,11%
AEX 874,48 -0,66 -0,08%
vlag naam koers verschil relatief verschil
AEX 874,48 -0,66 -0,08%
AEX GR 3.431,46 -1,13 -0,03%
Germany40^ 19.258,80 -37,18 -0,19%
FTSE 100 8.278,34 +19,73 +0,24%
EURO50 4.734,14 -24,78 -0,52%
US30^ 44.857,00 +7,20 +0,02%
Nasd100^ 20.651,00 -272,40 -1,30%
US500^ 5.996,97 -25,19 -0,42%
Japan225^ 37.825,50 -507,70 -1,32%
VD-NEW 15,60 +0,26 +1,69%
#/^ Index indications calculated real time, zie disclaimer